|
 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Financial Support |
 |
Target Audience |
 |
Credit Information |
Major Depressive Disorder and Treating to Remission
neuroscienceCME Multimedia Snack
Premiere Date: Wednesday, December 4, 2013This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 4, 2014
Note: Credit Is No Longer Available
 | Ned H. Kalin, MD Hedberg Professor and Chair Department of Psychiatry University of Wisconsin School of Medicine and Public Health--Madison Director, HealthEmotions Research Institute Madison, WI Editor-in-Chief – American Journal of Psychiatry |
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
After the initiation of antidepressant monotherapy, the importance of consistently and carefully monitoring patients with major depressive disorder (MDD) cannot be overemphasized. Most clinicians would agree that there is a clinical urgency to identify partial responders and nonresponders. Having a plan in place and clinical tools available helps optimize this process and forms the basis of timely, measurement-based care.
Compelling evidence indicates that residual symptoms at the end of a depressive episode, even if these symptoms are mild, are associated with significant psychosocial disability, an increased risk of relapse, and a more than three times increased speed of relapse return. Presence of residual symptoms may even be a stronger predictor of MDD recurrence than a history of multiple MDD episodes.
This educational activity will help clinicians improve monitoring of patients with MDD to identify cases that are treatment-resistant to monotherapy and to initiate the best, appropriate clinical plan to optimize pharmacotherapy toward a goal of preventing relapse.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Evaluate all patients with MDD for residual symptoms and implement strategies to improve response and prevent or minimize relapse.
At the end of this CE activity, participants should be able to:
- Devise and implement individualized treatment plans for patients with treatment-resistant depression (TRD), where plans include augmentation and/or adjunctive therapies with the goal of remission.
- Use validated rating scales and questionnaires, in concert with measurement-based care principles, to objectively measure the changes in clinical status over time of patients being treated for major depressive disorder (MDD) and to identify partial or non-responders to treatment.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Psychiatrists, primary care physicians, pharmacists, and other health care practitioners who manage patients with major depression
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number:
0376-0000-13-023-H01-P
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST830 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kalin has disclosed that he received grant support from National Institute for Mental Health. He serves on the Scientific Advisory Board of CeNeRx Biopharma; and Corcept Therapeutics. He is a stockholder/maintains equity options in CeNeRx Biopharma; and Corcept Therapeutics; and is the owner of Promoter Neurosciences, LLC. He hold patents for the following: promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences: U.S. Patent issued on 07-04-06; patent #7071323, U.S. Patent issued on 05-12-09; patent #7,531,356
Promoter sequences for urocortin II and the use thereof: U.S. Patent issued on 08-08-06; patent #7087385
Promoter sequences for corticotropin-releasing factor binding protein and use thereof: U.S. Patent issued on 10-17-06; patent #7122650.
Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Allergan, Inc.; Eli Lilly and Company; Shire Pharmaceuticals, Inc.; SK Pharma; Roche; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; Skyland Trail; and AstraZeneca Pharmaceuticals (2009). He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Gratitude America; Cook Pharma, Inc. (2010); NovaDel Pharma, Inc; and Skyland Trail. He is a stockholder of CeNeRx BioPharma; NovaDel Pharma, Inc., PharmaNeuroBoost; Reevax Pharmaceuticals LLC; and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Tony Graham, MD (peer review) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly USA, LLC do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-058-120413-11
